Skip to content

Edwards Lifesciences

US · EW #442 by market cap Listed 1970
101.85 -2.03 -1.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Official SEC filings

Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 02:43 UTC.

FormFiledOriginal document
8-K2026-11-19Read on SEC.gov
10-Q2026-11-04Read on SEC.gov
8-K2026-11-04Read on SEC.gov
8-K2026-08-28Read on SEC.gov
10-Q2026-08-04Read on SEC.gov
8-K2026-07-23Read on SEC.gov
8-K2026-05-08Read on SEC.gov
10-Q2026-05-06Read on SEC.gov

SEC annual financial snapshot

Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-22 07:51 UTC.

MetricUSDBasisPeriod endFiledSource
Revenue$6.07BAnnual2025-12-312026-02-2510-K
Net income$1.07BAnnual2025-12-312026-02-2510-K
Operating cash flow$1.60BAnnual2025-12-312026-02-2510-K
Total assets$13.70BAs of2025-12-312026-02-2510-K
Total liabilities$3.36BAs of2025-12-312026-02-2510-K
Stockholders’ equity$10.34BAs of2025-12-312026-02-2510-K
Cash and cash equivalents$2.94BAs of2025-12-312026-02-2510-K

✦ Quant Financial Health how this is computed

Good
  • Altman Z-Score is 13.18, above the 3.0 "safe zone" threshold.
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

✦ Quant Revenue Concentration how this is computed

Single-engine
  • Transcatheter Aortic Valve Replacement is the largest reported line at 72.38% of revenue, across 3 reported segments.
  • The next-largest line, Surgical, is a distant second at 15.41% - a sharp slowdown here would have little to offset it.

Revenue annual, last 8 years

Latest year +11.55% YoY

Margins

Gross margin
78.01%
Operating margin
26.97%
Net margin
17.69%

Key ratios & quality

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Revenue 3.72B4.35B4.39B5.23B4.46B5.01B5.44B6.07B
Gross profit 2.78B3.23B3.31B3.98B3.74B4.03B4.32B4.73B
Selling & admin expenses 1.09B1.24B1.23B1.49B1.36B1.58B1.79B2.09B
Research & development 622.20M752.70M760.70M903.10M843.60M962.90M1.05B1.08B
Operating profit 1.07B1.24B1.32B1.59B1.54B1.49B1.48B1.64B
Pretax profit 761.40M1.17B916.70M1.70B1.52B1.37B1.55B1.27B
Tax 39.20M119.60M93.30M198.90M195.50M152.40M152.10M216.90M
Net profit 722.20M1.05B823.40M1.50B1.52B1.40B4.17B1.07B
Basic EPS 12122272
Diluted EPS 1.131.641.302.382.442.306.971.83

Balance sheet

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Total current assets 2.29B2.98B3.09B3.18B3.10B4.04B6.29B6.74B
Cash & ST investments 956.50M1.52B1.40B1.47B1.22B1.63B3.98B4.23B
Inventory 607.00M640.90M802.30M726.70M875.50M903.50M1.09B1.13B
Total assets 5.32B6.49B7.24B8.50B8.29B9.36B13.06B13.70B
Total current liabilities 876.60M902.40M893.90M1.03B1.02B1.20B1.51B1.81B
Short-term debt --25.50M27.20M25.50M25.50M22.90M23.40M24.50M
Long-term debt 593.80M594.40M595.00M595.70M596.30M597.00M597.70M598.30M
Total liabilities 2,183,300,000.002,339,800,000.002,662,800,000.002,666,700,000.002,485,800,000.002,643,800,000.002,992,400,000.003,359,600,000.00
Total equity 3.14B4.15B4.57B5.84B5.81B6.72B10.06B10.34B
Retained earnings 2.69B3.74B4.57B6.07B7.59B8.99B13.17B14.24B

Cash flow

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Operating cash flow 926.70M1.18B1.05B1.73B1.22B895.80M542.30M1.60B
Depreciation & amortization 77.40M89.30M107.20M134.80M139.60M144.90M155.20M156.60M
Free cash flow 685.00M904.50M647.00M1.40B953.40M629.50M259.90M1.34B
Dividends paid ----------------
Stock buybacks / issuance -795.50M-263.30M-625.40M-512.80M-1.73B-879.60M-1.16B-893.40M
Ending cash balance 715.90M1.18B1.20B867.40M772.60M1.15B3.06B2.94B

Returns & efficiency

Line item 2018 2019 2020 2021 2022 2023 2024 2025
ROE % 23.6928.7318.8828.8826.1422.5250.1510.56
ROA % 13.1117.7312.0019.1018.1215.8937.248.03
ROIC % 20.2124.1416.1825.5023.1519.6345.278.74
5-year avg ROE % 26.2723.3422.8924.2225.2625.0329.3127.65
EBIT margin % 21.2627.3021.2632.8833.1926.9128.8221.31
FCF / sales % 18.4020.7214.7526.8017.7110.484.7822.00
Current ratio 2.613.313.463.083.033.384.183.72
Quick ratio 1.702.342.242.071.872.063.122.83
Debt / assets 11.1510.469.608.128.347.325.365.15
LT debt / equity 18.9115.7514.6011.3911.479.966.776.59
Interest coverage 26.4657.3559.0293.5093.0591.8079.1963.40
Revenue CAGR (3Y) % 14.2913.638.4912.020.884.531.3010.77
Net income CAGR (3Y) % 13.4322.5012.1627.6813.2819.4240.56-10.98
FCF CAGR (3Y) % 15.6222.92-7.7926.971.77-0.91-42.9911.88

Revenue breakdown most recent period

Business

Transcatheter Aortic Valve Replacement72.38%
Surgical15.41%
Transcatheter Mitral and Tricuspid Therapies12.21%

Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.

Edwards Lifesciences discussion 0 comments

Add a comment